A phase II study of trifluridine/tipiracil in combination with ramucirumab in advanced, refractory gastric, or gastroesophageal junction adenocarcinomas
The combination of ramucirumab and FTD/TPI demonstrated well-manageable safety profile. Our study did not meet primary endpoint. Ongoing clinical trials will help us understand if ramucirumab plus FTD/TPI is noninferior to ramucirumab/paclitaxel. The trial was registered at www.clinicaltrials.gov (NCT03686488).
Authors
- Rutika Mehta (ORCID: https://orcid.org/0000-0002-1454-053X)
- Richard D. Kim (ORCID: https://orcid.org/0000-0002-8448-844X)
- Maricela Martínez Jiménez (ORCID: https://orcid.org/0000-0002-6690-1480)
- Dae Won Kim (ORCID: https://orcid.org/0000-0003-2151-2841)
- Youngchul Kim (ORCID: https://orcid.org/0000-0002-2307-0330)
Institutions
- Cornell University (US)
- Moffitt Cancer Center (US)
- Presbyterian Hospital (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1093/oncolo/oyaf303
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00